34385PAA6

Standard Biotools Inc.

Could not find a ticker for this position, may be a filing error

A maker of scientific instruments used by biomedical researchers to study individual cells and proteins. Its three platforms—CyTOF mass cytometry, Hyperion spatial proteomics, and Biomark genomics—are sold to academic labs, translational centers, and biopharma companies. Founded in 1999 as Mycometrix and renamed Fluidigm in 2001 (a play on the "fluid" microchips it builds), the company became Standard BioTools in 2022, after its microfluidics "integrated fluidic circuits" were born from a Caltech lab that manipulates fluids on chips much like electronics handle electrons.

NOTEUnderlying: LABCUSIP: 34385PAA6HealthcareUS1 derivative reporter

5.25% Convertible Senior Notes due 2024

Ownership Activity Financials Filings

Insiders

Ranked by how much each holding moved in the last 3 years

Insider

Casdin Eli +8 co-filersDirector, 10% owner, Director, 10% owner · 17 transactions

136.13M—

as of Mar 2025

Granted 58.2K · Bought 10.92M

Casdin Eli +8 co-filersDirector, Director, 10% owner · 14 transactions

130.66M—

as of Jun 2024

Granted 46.47M · Bought 2.30M

Casdin Eli +7 co-filersDirector, Director, 10% owner · 24 transactions

105.62M—

Bought 12.71M

Casdin EliDirector, 10% owner · 11 transactions

91.84M—

Granted 21.86M

Casdin Private Growth Equity Fund GP, LLC +7 co-filersDirector, Director, 10% owner · 2 transactions

15.19M—

as of Jan 2024

Granted 13.99M

Egholm MichaelPresident & CEO, Director · 25 transactions

6.14M+2872.1%

Granted 7.04M · Sold 15.3K

Kim Hanjoon AlexChief Financial Officer · 20 transactions

2.53M+3511.8%

Granted 2.78M · Sold 4.2K

Mackay SeanSVP & Chief Business Officer · 12 transactions

1.48M—

Granted 1.05M · Sold 38.6K

Cox TroyDirector · 7 transactions

475.7K—

Granted 460.5K

Black Jeffrey G.SVP & Chief Financial Officer · 6 transactions

421.6K+390.3%

as of Aug 2024

Granted 365.8K

Carey Thomas D.Director · 6 transactions

344.5K—

Granted 423.9K

Eloi Fenel MDirector · 3 transactions

335.3K+240.5%

Granted 236.8K

Witney FrankDirector · 3 transactions

314.2K+306.1%

Granted 236.8K

Hibbs Kathy LDirector · 4 transactions

236.8K—

Granted 316.2K

Madaus Martin DDirector · 1 transaction

104.1K+1.5%

as of Oct 2023

Granted 1.6K

Insider	Stake change	Holds now	Granted / vested	Bought	Sold
Casdin Eli +8 co-filersDirector, 10% owner, Director, 10% owner · 17 transactions	—	136.13Mas of Mar 2025	58.2K	10.92M	—
Casdin Eli +8 co-filersDirector, Director, 10% owner · 14 transactions	—	130.66Mas of Jun 2024	46.47M	2.30M	—
Casdin Eli +7 co-filersDirector, Director, 10% owner · 24 transactions	—	105.62M	—	12.71M	—
Casdin EliDirector, 10% owner · 11 transactions	—	91.84M	21.86M	—	—
Casdin Private Growth Equity Fund GP, LLC +7 co-filersDirector, Director, 10% owner · 2 transactions	—	15.19Mas of Jan 2024	13.99M	—	—
Egholm MichaelPresident & CEO, Director · 25 transactions	+2872.1%	6.14M	7.04M	—	15.3K
Kim Hanjoon AlexChief Financial Officer · 20 transactions	+3511.8%	2.53M	2.78M	—	4.2K
Mackay SeanSVP & Chief Business Officer · 12 transactions	—	1.48M	1.05M	—	38.6K
Cox TroyDirector · 7 transactions	—	475.7K	460.5K	—	—
Black Jeffrey G.SVP & Chief Financial Officer · 6 transactions	+390.3%	421.6Kas of Aug 2024	365.8K	—	—
Carey Thomas D.Director · 6 transactions	—	344.5K	423.9K	—	—
Eloi Fenel MDirector · 3 transactions	+240.5%	335.3K	236.8K	—	—
Witney FrankDirector · 3 transactions	+306.1%	314.2K	236.8K	—	—
Hibbs Kathy LDirector · 4 transactions	—	236.8K	316.2K	—	—
Madaus Martin DDirector · 1 transaction	+1.5%	104.1Kas of Oct 2023	1.6K	—	—

Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.